



2021 American Society of Clinical Oncology Annual Meeting

TAKEDA ONCOLOGY
SPONSORED ABSTRACTS

Learn more at [takedaoncology.com](https://www.takedaoncology.com)



©2021 Millennium Pharmaceuticals, Inc. All rights reserved.



ONCOLOGY

ABSTRACT #	TITLE	SESSION
CHRONIC MYELOID LEUKEMIA		
ABSTRACT 7000	OPTIC primary analysis: a dose-optimization study of 3 starting doses of ponatinib (PON)	Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and Allotransplant ORAL PRESENTATION JUNE 4, 2021 2:30-5:30 P.M. ET 
EGFR EXON20 INSERTION+ MNSCLC		
ABSTRACT 9014	Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 trial	POSTER DISCUSSION SESSION Lung Cancer - Non-Small Cell Metastatic 
ABSTRACT 9098	Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations	POSTER SESSION Lung Cancer - Non-Small Cell Metastatic 
ALK+ NSCLC		
ABSTRACT 9071	Brigatinib in ALK+ crizotinib-refractory non-small cell lung cancer (NSCLC): Final results of the Phase 1/2 and ALTA trials	POSTER SESSION Lung Cancer - Non-Small Cell Metastatic 
ABSTRACT 9042	Brigatinib in Japanese patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): First results from the J-ALTA tyrosine kinase inhibitor (TKI)-naive expansion cohort	POSTER SESSION Lung Cancer - Non-Small Cell Metastatic
HIGHER-RISK MYELODYSPLASTIC SYNDROMES		
ABSTRACT 7042	Model-based analysis to support dose selection of pevonedistat (PEV) combined with azacitidine (AZA) in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML)	POSTER SESSION Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and Allotransplant 
MULTIPLE MYELOMA		
ABSTRACT 8020	Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma (MM) patients: A global, multicenter, randomized, open-label, phase 2 trial	POSTER DISCUSSION SESSION Hematologic Malignancies Plasma Cell Dyscrasia 
HODGKIN LYMPHOMA		
ABSTRACT 7528	Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYAs) with Stage III or IV Hodgkin Lymphoma: a Subgroup Analysis From the Phase 3 ECHELON-1 Study	POSTER SESSION Hematologic Malignancies - Lymphoma and Chronic Lymphocytic Leukemia 
PIPELINE		
ABSTRACT TPS2667	Phase 1/2 study of the novel SUMOylation inhibitor TAK-981 in adult patients (pts) with advanced or metastatic solid tumors or relapsed/refractory (RR) hematologic malignancies	POSTER SESSION Developmental Therapeutics - Immunotherapy 
ABSTRACT TPS2670	A phase 1 dose-escalation study of intravenously (IV) administered TAK-676, a novel STING agonist, alone and in combination with pembrolizumab in patients (pts) with advanced or metastatic solid tumors	POSTER SESSION Developmental Therapeutics - Immunotherapy
ABSTRACT 3050	A phase 1 study of TAK-164, an anti-guanylyl cyclase C (GCC) antibody-drug conjugate (ADC), in patients (pts) with advanced gastrointestinal (GI) cancers expressing GCC	POSTER SESSION Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology